Case-Based Learning: Compounding Error Causing an Unexpected Drug Concentration

Abstract

Medication compounding errors remain a significant yet underrecognized contributor to adverse drug events in clinical practice. This article reviews a case of unexpected drug concentration resulting from a compounding error, discusses epidemiology, pathophysiology, risk factors, clinical presentation, diagnosis, management, and emerging strategies for prevention. The review emphasizes the importance of vigilance, standardization, and guideline adherence to mitigate risks associated with extemporaneous drug preparation, and provides evidence-based recommendations for healthcare professionals.

Introduction

Compounding, the process of preparing personalized medications by combining, mixing, or altering ingredients, is a cornerstone in individualized patient care, especially for populations requiring non-standard doses or formulations. However, the complexity of compounding introduces unique risks, including dosing inaccuracies that can lead to unanticipated drug concentrations, toxicity, or therapeutic failure. In this review, we analyze a representative case of compounding error, contextualizing it within the current literature to provide clinicians with actionable insights for risk mitigation and patient safety.

Epidemiology / Disease Burden

Compounding errors account for a substantial proportion of medication-related adverse events, particularly in pediatric, geriatric, and critical care settings where off-label or unlicensed formulations are frequently employed. According to recent surveillance data, up to 25% of adverse drug events in hospitalized children are linked to compounding errors, with similar trends noted in specialty pharmacies. The true incidence is likely underestimated due to underreporting and challenges in error detection, especially for drugs with narrow therapeutic indices. The global burden is compounded by variable regulatory oversight and disparities in compounding standards between regions.

Pathophysiology

The pathophysiological consequences of compounding errors depend on the nature and magnitude of the deviation from intended drug concentrations. Over-concentration may precipitate acute toxicity, organ dysfunction, or fatal outcomes, while under-concentration can result in subtherapeutic exposure and treatment failure. Mechanistically, errors may arise from incorrect weighing, dilution, or measurement, leading to altered pharmacokinetics and pharmacodynamics. For example, excessive concentration of cardiac glycosides can cause arrhythmias, while insufficient anticonvulsant compounding may precipitate breakthrough seizures. The variability in compounded product stability and bioavailability further complicates outcome prediction.

Risk Factors

Multiple factors predispose to compounding errors. These include inadequate training, lack of standardized protocols, high workload, use of manual calculations, and poor communication between prescribers and pharmacy personnel. Medications with complex compounding procedures, low therapeutic indices, or requiring micro-dosing are at higher risk. Environmental factors, such as insufficient lighting or interruptions, and system-level issues, such as absence of double-checks and limited access to validated formulations, also contribute. Patient-specific factors, such as age and organ dysfunction, may amplify susceptibility to adverse outcomes from even minor deviations in drug concentration.

Clinical Features

Clinical manifestations of compounding errors vary widely depending on the drug, degree of error, and patient comorbidities. Acute toxicity may present with neurological, cardiovascular, hepatic, or renal compromise. For example, excessive local anesthetic concentration can result in CNS toxicity, while under-dosing of antibiotics may lead to persistent infection. Non-specific symptoms such as nausea, vomiting, or altered mental status are common, necessitating a high index of suspicion, particularly when clinical response deviates from expectations or when new symptoms emerge post-initiation of compounded therapy.

Diagnosis

Diagnosis of compounding error-induced abnormal drug concentration requires integration of clinical, laboratory, and pharmaceutical data. Suspicion should be raised by unexpected pharmacologic effects, therapeutic failure, or toxicity without an alternative explanation. Quantitative drug assays, where available, provide definitive evidence. Root cause analysis involving review of compounding records, process audits, and reconciliation of prescribed versus dispensed concentrations is essential. Engaging pharmacy staff and employing incident reporting systems can facilitate identification and prevention of recurrent errors.

Treatment & Management

Immediate management involves cessation or adjustment of the offending medication, supportive care, and, where appropriate, administration of antidotes or specific therapies (e.g., activated charcoal, intravenous fluids, or hemodialysis for certain toxicities). Close monitoring for delayed effects is warranted. Multidisciplinary team involvement, including clinical pharmacists, is critical in recalculating correct doses and reinitiating therapy safely. Patient and caregiver communication is essential to ensure informed consent and minimize harm.

Recent Advances / Emerging Therapies

Technological advancements, such as automated compounding devices, barcode verification, and smart infusion systems, have shown promise in reducing human error. Standardized compounding protocols, utilization of pre-mixed commercial products when available, and electronic prescribing integrated with pharmacy information systems enhance safety. Ongoing research in pharmacogenomics and personalized dosing algorithms may further optimize individualized therapy, minimizing reliance on manual compounding. Simulation-based staff training and continuous professional development are increasingly recognized as vital components of error prevention strategies.

Guideline Recommendations

Professional bodies such as the United States Pharmacopeia (USP), American Society of Health-System Pharmacists (ASHP), and equivalent international organizations have issued recommendations aimed at standardizing compounding practices. Key guidelines emphasize competency-based staff training, mandatory double-checking of calculations and procedures, rigorous documentation, and environmental controls. Regular audit and feedback, error reporting, and root cause analysis are advocated. Preference for commercially available, quality-assured products is recommended where possible. Institutions are encouraged to implement risk assessment frameworks and foster a culture of safety and transparency.

Conclusion

Compounding errors remain a significant threat to patient safety, with potential for severe and unexpected drug concentrations leading to adverse outcomes. Vigilance, adherence to evidence-based guidelines, and adoption of technological and educational innovations are paramount in minimizing risk. A multidisciplinary, system-based approach is essential to safeguard against compounding-related harm and to ensure optimal therapeutic outcomes in clinical practice.